Tag Archives: therapeutics

BIO Is Almost Here – What To Consider Before Entering New Therapeutic Areas

BIO International Convention

Over the past decade, the biopharmaceutical industry has witnessed a shift towards specialty care. From 2008 to 2014, FDA specialty drug approvals jumped from 33 percent to over 50 percent of all approvals. In 2014, the FDA approved a record 19 specialty care medicines. Given this new reality, companies are expanding the focus of their R&D into new therapeutic areas to address difficult-to-treat, specialty care conditions. Building successful franchises requires a strategic approach to determine the Read More >

Business and Investments, Events  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,

State of the Industry for Emerging Therapeutic Companies

Emerging Therapeutic Company Investment and Deal Trends

Emerging therapeutic companies are at their strongest point in a decade. In our new report on investment and deal trends, the BIO Industry Analysis team shows how this segment within the biotech industry has been faring over the last 10 years. The annual aggregate totals show that for almost every funding or deal activity analyzed, 2014 was the peak year of the last decade. A strong public market, a revitalized private funding environment, and a Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,

My Journey From BioGENEius to PhD Student

scientist, lab

For as long as I can remember, I’ve known that research and biotechnology would be a large part of my life. Science has always been a passion of mine, and I was lucky to be guided into the laboratory at an early age. In 11th grade I met my mentor, Dr. Angela Crawley, when she was a post-doctoral fellow working in Dr. Jonathan Angel’s laboratory at the Ottawa Hospital Research Institute. Here, I was introduced Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

2012: A Critical Year for Biotechnology

U.S. Capitol Building - Congress

In 2012, we must continue to look for ways to reduce risk; enhance reward; reduce uncertainty; and reinforce the position of the industry as a major contributor resolving society’s most pressing needs. Policies to encourage investment in innovation and to speed discovery to scientific breakthroughs simply must be the priority in 2012. The industry relies on a policy and regulatory environment that encourages innovation for much needed treatments and cures for some of the most Read More >

Public Policy  |  1 Comment  |  Email This Post
Tags: , , , , , ,

Foundation Fighting Blindness Invests in Gene Therapy Research Projects

567497167_0ee54c371c_z

Recently, the Foundation Fighting Blindness announced an $8.25 million investment in six new gene therapy research projects targeted to have treatments ready for clinical trials within three years. The projects include the following: The Institut de la Vision in Paris and the Friedrich Miescher Institute in Basel, Switzerland, are developing a gene therapy that may revive degenerating cones and potentially enable them to regain their ability to respond to light and provide vision. The treatment Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , ,